Jiangsu Bochuangyuan Biopharmaceutical Technology

Jiangsu Bochuangyuan Biopharmaceutical Technology is a clinical-stage biotechnology company headquartered in Taizhou, China, focused on developing innovative small molecule therapies for dermatological and autoimmune diseases. Founded by Dr. Luhua Wang, the company specializes in high-unmet-need conditions such as psoriasis, atopic dermatitis, and vitiligo. Its lead candidate, CKL-01, is a topical PDE4 inhibitor that has demonstrated promising results in clinical trials for the treatment of psoriasis. Bochuangyuan leverages its expertise in medicinal chemistry and topical drug delivery to build a specialized pipeline of targeted inhibitors. The company is a key player within the China Medical City (CMC) ecosystem and has attracted investment from prominent venture capital firms to advance its clinical programs.